Mode
Text Size
Log in / Sign up
Phase 4 Completed N=274 Treatment

Digital Auscultation Test - IPF Data Collection

Source: ClinicalTrials.gov NCT03503188 ↗
Enrolled (actual)
274
Serious AEs
Results posted
Jan 2020
Primary outcomePrimary: Main Study - The Percentage of Collected Auscultation Points — 100; 100 PercentageOfAuscultationPointsCollected
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The aim of this study is the data collection for patients with IPF and symptom matched controls to create a database of lung auscultation sounds and basic patient characteristics.

Outcome Measures

OutcomeResultp-value
PRIMARY
Main Study - The Percentage of Collected Auscultation Points
100; 100
SECONDARY
Entire Study - Participants Reported Symptoms of Respiratory Disease - Dyspnoea Recorded Via a Modified Medical Research Council (MRC) Scale
29; 40; 41; 28; 31; 44
SECONDARY
Entire Study - Participants Reported Symptoms of Respiratory Disease - Cough and Sputum
41; 64; 27; 16; 13; 27
SECONDARY
Entire Study - Smoking Status
85; 78; 1; 26; 42; 41
SECONDARY
Entire Study - Body Mass Index (BMI)
25.31; 23.99
SECONDARY
Sub Study - The Percentage of Collected Auscultation Points
100; 100; 100; 100

Eligibility Criteria

Inclusion Criteria

  • Male or female patients
  • Age ≥ 45 years at the day of the study visit
  • Diagnosis:
  • For patients with confirmed Idiopathic Pulmonary Fibrosis (IPF) diagnosis - a clinical diagnosis of IPF within the last 24 months from the day of the study visit, according to the American Thoracic Society (ATS)/ European Respiratory Society (ERS) 2011 guideline [P11-07084] or
  • For the symptom matched control - patients without a IPF diagnosis but with one of the confirmed current conditions as:
  • asthma diagnosed according to GINA guidelines,
  • COPD diagnosed according to GOLD guidelines,
  • pneumonia,
  • upper respiratory tract infection, or
  • acute bronchitis.
  • Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the study

Exclusion Criteria

  • Any other current respiratory condition other than the pulmonary disease which qualified the patient eligibility based on inclusion criterion 3
  • Any condition, according to investigator's assessment, which will not allow the patient to comply with protocol assessments or need a legal representative
  • Patients with a history of lobectomy, pneumonectomy or lung transplant
  • Patients with a Body Mass Index (BMI) >30,0 kg/m²
  • Previous enrolment in this study
  • Women who are pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03503188). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search